{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:09:59Z","timestamp":1725275399569},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T00:00:00Z","timestamp":1401840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Physical and Rehabilitation Medicine"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.rehab.2014.05.009","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T23:48:20Z","timestamp":1401752900000},"page":"321-328","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current and future drugs for treatment of MS-associated bladder dysfunction"],"prefix":"10.1016","volume":"57","author":[{"given":"K.-E.","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rehab.2014.05.009_bib0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","article-title":"Pathology of demyelinating diseases","volume":"7","author":"Popescu","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1474-4422(08)70191-1","article-title":"Grey matter pathology in multiple sclerosis","volume":"7","author":"Geurts","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0050","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rehab.2014.05.009_bib0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","article-title":"The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms","volume":"26","author":"Engelhardt","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/B978-0-444-52001-2.00014-5","article-title":"The clinical course of multiple sclerosis","volume":"122","author":"Confavreux","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0175","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.4081\/ni.2013.e23","article-title":"Urinary dysfunction in women with multiple sclerosis: analysis of 61 patients from Rio de Janeiro, Brazil","volume":"5","author":"de Almeida","year":"2013","journal-title":"Neurol Int"},{"key":"10.1016\/j.rehab.2014.05.009_bib0155","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.clineuro.2013.06.018","article-title":"Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis","volume":"115","author":"De Ridder","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.rehab.2014.05.009_bib0065","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0090-4295(92)90045-X","article-title":"Lower urinary tract dysfunction in multiple sclerosis","volume":"39","author":"Mayo","year":"1992","journal-title":"Urology"},{"key":"10.1016\/j.rehab.2014.05.009_bib0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/jnnp.56.3.245","article-title":"Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis","volume":"56","author":"Betts","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.rehab.2014.05.009_bib0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0003-9993(98)90003-X","article-title":"Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases","volume":"79","author":"Gallien","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.rehab.2014.05.009_bib0145","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0022-5347(01)61760-9","article-title":"Multiple sclerosis and the urologist","volume":"161","author":"Litwiller","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0060","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.purol.2013.06.010","article-title":"Autonomic nervous system alteration in multiple sclerosis patients with urinary symptoms. Clinical, urodynamic and cardiovascular study","volume":"23","author":"Amarenco","year":"2013","journal-title":"Prog Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","article-title":"Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"62","author":"Madhuvrata","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0055","first-page":"CD004193","article-title":"Anticholinergics for urinary symptoms in multiple sclerosis","volume":"1","author":"Nicholas","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rehab.2014.05.009_bib0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11255-006-0071-9","article-title":"Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin","volume":"38","author":"Kilicarslan","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0070","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0022-5347(01)67524-4","article-title":"Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?","volume":"153","author":"O\u2019Riordan","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.disamonth.2013.03.013","article-title":"The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients","volume":"59","author":"Sand","year":"2013","journal-title":"Dis Mon"},{"key":"10.1016\/j.rehab.2014.05.009_bib0125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11934-012-0266-9","article-title":"The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review","volume":"13","author":"Tubaro","year":"2012","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.rehab.2014.05.009_bib0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11539000-000000000-00000","article-title":"Role of cannabinoids in multiple sclerosis","volume":"25","author":"Zajicek","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.rehab.2014.05.009_bib0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/978-3-642-16499-6_20","article-title":"Cannabinoids: potential targets for bladder dysfunction","volume":"202","author":"Ruggieri","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/nau.22442","article-title":"Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction","volume":"33","author":"Hedlund","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.rehab.2014.05.009_bib0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/0269215503cr581oa","article-title":"A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms","volume":"17","author":"Wade","year":"2003","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.rehab.2014.05.009_bib0095","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rehab.2014.05.009_bib0020","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","article-title":"The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)","volume":"17","author":"Freeman","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.rehab.2014.05.009_bib0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458504ms1063oa","article-title":"An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis","volume":"10","author":"Brady","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.rehab.2014.05.009_bib0180","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.rehab.2014.05.009_bib0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eururo.2011.09.002","article-title":"Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats","volume":"61","author":"Strittmatter","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0130","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinum toxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","article-title":"Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis","volume":"185","author":"Khan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0045","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/ern.12.61","article-title":"Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis","volume":"12","author":"Goessaert","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.rehab.2014.05.009_bib0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1179\/2045772313Y.0000000116","article-title":"Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review","volume":"36","author":"Linsenmeyer","year":"2013","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.rehab.2014.05.009_bib0170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7224\/1537-2073.2012-031","article-title":"Advances in the management of neurogenic detrusor overactivity in multiple sclerosis","volume":"15","author":"Yonnet","year":"2013","journal-title":"Int J MS Care"},{"key":"10.1016\/j.rehab.2014.05.009_bib0030","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1590\/S1677-55382011000500012","article-title":"Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients","volume":"37","author":"Deffontaines-Rufin","year":"2011","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.rehab.2014.05.009_bib0165","first-page":"247","article-title":"Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action","volume":"7","author":"Damal","year":"2013","journal-title":"Biologics"},{"issue":"4","key":"10.1016\/j.rehab.2014.05.009_bib0160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/joim.12203","article-title":"Established and novel disease-modifying treatments in multiple sclerosis","volume":"275","author":"Cross","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.rehab.2014.05.009_bib0120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clin Proc"}],"container-title":["Annals of Physical and Rehabilitation Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187706571401728X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187706571401728X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T21:06:13Z","timestamp":1544475973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187706571401728X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S187706571401728X"],"URL":"https:\/\/doi.org\/10.1016\/j.rehab.2014.05.009","relation":{},"ISSN":["1877-0657"],"issn-type":[{"value":"1877-0657","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future drugs for treatment of MS-associated bladder dysfunction","name":"articletitle","label":"Article Title"},{"value":"Annals of Physical and Rehabilitation Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rehab.2014.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}